Riskpilot← Back to searchSign inGet full accessDiafysen AB
ABActiveOrg 5565151684Jarlaplan 4 Lgh 1401General medical practice activities · NACE 8621Est. 19950 employees
Revenue 2024
SEK -640
-100% vs 2023
EBITDA margin
23447.2%
+95% vs 2023
Equity ratio
97.5%
Financial strength
Net profit 2024
SEK -150K
+95% vs 2023
| Revenue | SEK -640 | -100% |
| EBITDA | SEK -150K | +95% |
| Net profit | SEK -150K | +95% |
| Total assets | SEK 6,6M | -1% |
| Equity | SEK 6,4M | -2% |
| Employees | 0 | — |
Legal name
Diafysen AB
Org number
5565151684
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
18 juli 1995
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva läkarpraktik samt handel med antikviteter, konst, värdepapper, fast och lös egendom och därmed förenlig verksamhet.
Address
Jarlaplan 4 Lgh 1401
Phone
+46708771120
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 116 | 0 | 0 | −2 623 | −1 |
| Staff expenses | — | — | −6 | — | — |
| EBITDA | −397 | −891 | −198 | −2 767 | −150 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −397 | −891 | −490 | −2 767 | −150 |
| Net financials | 2 | 2 | −1 | 0 | 0 |
| Profit before tax | −104 | −889 | −491 | −2 767 | −150 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −104 | −889 | −491 | −2 767 | −150 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 11 106 | 10 192 | 9 442 | 6 664 | 6 597 |
| Equity | 11 028 | 10 139 | 9 348 | 6 581 | 6 431 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 78 | 54 | 95 | 83 | 166 |
| Total debt | 78 | 54 | 95 | 83 | 166 |
EBITDA margin
-15006200.0%
This company
15.8%
Market median
-94976049% vs market
20202024
Equity ratio
97.5%
This company
38.2%
Market median
+155% vs market
20202024
Return on equity
-2.3%
This company
18.4%
Market median
-113% vs market
20202024
Net profit margin
-14961400.0%
This company
8.1%
Market median
-184708742% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Diafysen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inger Marianne Sjöblom | Deputy Board Member | 0 companies |
| Bernhard Katzenstein | Board of Directors | 0 companies |